In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Moderna has announced that it plans to cut down 10% of its workforce by the end of the year. CEO Stephane Bancel said in a ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...